Hugging Face's logo

Datasets:
bigbio
/
czi_drsm

Languages:
English
License:
Dataset card Files Community
czi_drsm / README.md
leonweber's picture
leonweber
Update czi_drsm based on git version f5bf778
16fe403
preview code
|
raw history blame
No virus
3.16 kB
metadata
language:
  - en
bigbio_language:
  - English
license: cc0-1.0
bigbio_license_shortname: cc0-1.0
multilinguality: monolingual
pretty_name: CZI DRSM
homepage: https://github.com/chanzuckerberg/DRSM-corpus
bigbio_pubmed: false
bigbio_public: true
bigbio_tasks:
  - TXTCLASS

Dataset Card for CZI DRSM

README.md

Dataset Description

Research Article document classification dataset based on aspects of disease research. Currently, the dataset consists of three subsets:

(A) classifies title/abstracts of papers into most popular subtypes of clinical, basic, and translational papers (~20k papers); - Clinical Characteristics, Disease Pathology, and Diagnosis - Text that describes (A) symptoms, signs, or ‘phenotype’ of a disease; (B) the effects of the disease on patient organs, tissues, or cells; (C) the results of clinical tests that reveal pathology (including biomarkers); (D) research that use this information to figure out a diagnosis. - Therapeutics in the clinic - Text describing how treatments work in the clinic (but not in a clinical trial). - Disease mechanism - Text that describes either (A) mechanistic involvement of specific genes in disease (deletions, gain of function, etc); (B) how molecular signalling or metabolism binding, activating, phosphorylation, concentration increase, etc.) are involved in the mechanism of a disease; or (C) the physiological mechanism of disease at the level of tissues, organs, and body systems. - Patient-Based Therapeutics - Text describing (A) Clinical trials (studies of therapeutic measures being used on patients in a clinical trial); (B) Post Marketing Drug Surveillance (effects of a drug after approval in the general population or as part of ‘standard healthcare’); (C) Drug repurposing (how a drug that has been approved for one use is being applied to a new disease).

(B) identifies whether a title/abstract of a paper describes substantive research into Quality of Life (~10k papers); - -1 - the paper is not a primary experimental study in rare disease - 0 - the study does not directly investigate quality of life - 1 - the study investigates qol but not as its primary contribution - 2 - the study's primary contribution centers on quality of life measures

(C) identifies if a paper is a natural history study (~10k papers).

  • -1 - the paper is not a primary experimental study in rare disease - 0 - the study is not directly investigating the natural history of a disease - 1 - the study includes some elements a natural history but not as its primary contribution - 2 - the study's primary contribution centers on observing the time course of a rare disease

These classifications are particularly relevant in rare disease research, a field that is generally understudied.

Citation Information 

# N/A